Mantle Cell Lymphoma
News
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
The researchers said the findings cast doubt on the ability of this CDK inhibitor to be effective in B-cell lymphomas.
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
Conference Coverage
Obinutuzumab provides strong early responses in untreated MCL
AMSTERDAM – A minimal residual disease rate as high as 85% is “unprecedented” in this population of patients, the lead investigator of the LYMA-...
News
CD23 expression linked to improved survival in MCL
Researchers found that mantle cell lymphoma cases that were CD23 positive had a higher frequency of leukemic nonnodal presentation and CD200...
News
Atypical case of cutaneous MCL mimics SPTCL
The unusual case shows the importance of molecular cytogenetics and/or immunohistochemistry when making a diagnosis in panniculitis-type lymphomas...
News
Inhibitor may overcome ibrutinib resistance in MCL
The inhibitor, IACS-010759, decreased tumor growth and prolonged survival in mouse models of ibrutinib-resistant lymphoma.
News
RIT consolidation may be an option for unfit MCL patients
Patients who could not undergo transplants had high rates of complete responses to radioimmunotherapy consolidation following induction...
Conference Coverage
Early data support R-BAC for post-BTKi mantle cell lymphoma
GLASGOW – The combination outperformed previously published data for other treatments in the relapsed/refractory setting.
News
MCL survival rates improve with novel agents
Median overall survival for mantle cell patients was between 52 and 57 months in two cancer registries. The researchers pointed to the impact of...
News
Worse survival seen among black patients with MCL
There was a survival gap between black and white patients, even though black patients with mantle cell lymphoma were more likely to be treated in...